Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. and keeping the price target at $90.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sam Slutsky has given his Buy rating due to a combination of factors related to CG Oncology, Inc.’s promising developments in their treatment for non-muscle invasive bladder cancer (NMIBC). The company is set to present significant findings at the Society of Urologic Oncology meeting, highlighting the efficacy of their oncolytic virus, cretostimogene, in treating high-risk, BCG-unresponsive NMIBC.
The results from their studies, such as the BOND-003 and CORE-008 cohorts, show promising outcomes with high rates of recurrence-free survival and complete response rates. These findings suggest a strong potential for inclusion in NCCN guidelines, similar to established treatments like Keytruda. Additionally, CG Oncology’s strategic focus on innovative therapies and their robust pipeline contribute to the positive outlook, supporting Slutsky’s Buy recommendation.
According to TipRanks, Slutsky is a 5-star analyst with an average return of 34.9% and a 49.65% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Cogent Biosciences, and Olema Pharmaceuticals.
In another report released today, RBC Capital also maintained a Buy rating on the stock with a $61.00 price target.